Question 1

Berapa harga saham GlaxoSmithKline PLC ADR hari ini?

Accepted Answer

Harga saat ini dari GlaxoSmithKline PLC ADR adalah 58.26 USD — telah menurun sebesar -0.08% dalam 24 jam terakhir. Lihat kinerja harga saham GlaxoSmithKline PLC ADR lebih dekat di chart lanjutan.

Question 2

Apa simbol saham GlaxoSmithKline PLC ADR?

Accepted Answer

Tergantung pada bursa, simbol saham dapat bervariasi. Misalnya, di bursa NYSE, saham GlaxoSmithKline PLC ADR diperdagangkan dengan simbol GSK.

Question 3

Apakah harga saham GSK naik?

Accepted Answer

Saham GSK telah meningkat sebesar 2.77% dalam minggu terakhir, telah meningkat sebesar 5.62% dalam bulan terakhir, dan telah meningkat sebesar 68.19% dalam setahun terakhir. Lihat lebih banyak data di GSK chart.

Question 4

Apa rekomendasi analis untuk GSK?

Accepted Answer

Per tanggal 12 Apr 2026, dari 6 rekomendasi analis, mayoritas memberikan nilai GSK sebagai hold.

Question 5

Berapa kapitalisasi pasar GSK?

Accepted Answer

Hingga hari ini, GSK memiliki kapitalisasi pasar sebesar 114.63B USD. Jelajahi daftar saham kami yang diperingkat berdasarkan kapitalisasi pasar untuk membandingkan GSK dengan saham lainnya.

Question 6

Apakah GSK merilis laporan keuangan?

Accepted Answer

Ya, Anda dapat melacak keuangan GSK dalam laporan tahunan dan kuartalan di Profit.com.

Question 7

Kapan tanggal laporan pendapatan GSK berikutnya?

Accepted Answer

GSK akan merilis laporan pendapatan berikutnya pada 29 Apr 2026. Ikuti perkembangan acara mendatang dengan Kalender Pendapatan kami.

Question 8

Berapa pendapatan GSK untuk kuartal terakhir?

Accepted Answer

GSK melaporkan pendapatan sebesar $0.6969 per saham untuk kuartal terakhir, lebih tinggi dibandingkan dengan estimasi $0.6378 per saham, menghasilkan kejutan 9.27%. Pendapatan yang diperkirakan untuk kuartal berikutnya adalah $1.2 per saham. Lihat lebih banyak detail tentang pendapatan GSK di Profit.com.

Question 9

Berapa pendapatan GSK untuk kuartal terakhir?

Accepted Answer

Pendapatan GSK untuk kuartal terakhir adalah 8.62B USD, lebih tinggi dibandingkan dengan estimasi 8.36B USD. Pendapatan yang diperkirakan untuk kuartal berikutnya adalah 8.48B USD. Lihat lebih banyak statistik di GSK laporan keuangan di Profit.com.

Question 10

Berapa Laba Bersih GSK untuk kuartal terakhir?

Accepted Answer

Laba bersih GSK untuk kuartal terakhir adalah 636M USD, sementara kuartal sebelumnya menunjukkan laba bersih 2.01B USD yang mencatatkan perubahan sebesar -68.41%. Lihat lebih banyak statistik di GSK laporan keuangan di Profit.com.

Question 11

Apakah GSK membayar dividen?

Accepted Answer

Ya, dividen GSK dibayar setiap kuartal. Dividen terakhir per saham adalah 0.66. Hingga hari ini, Dividend Yield (TTM)% adalah 3.04%.

Question 12

Berapa banyak karyawan yang dimiliki GSK?

Accepted Answer

Hingga 12 Apr 2026, GSK mempekerjakan sekitar 66841 karyawan. Periksa apakah GSK ada dalam daftar pengusaha terbesar kami.

Question 13

Apa itu EBITDA GSK?

Accepted Answer

EBITDA, yang mengukur kinerja operasional perusahaan, mencerminkan peningkatan efisiensinya. EBITDA GSK adalah 11.34B USD, dengan margin EBITDA saat ini sebesar 17.50%. Lihat lebih banyak statistik di laporan keuangan GSK di Profit.com.

Question 14

Bagaimana cara membeli saham GSK?

Accepted Answer

Seperti saham lainnya, saham GSK diperdagangkan di bursa saham seperti NYSE. Cara termudah untuk membelinya adalah melalui broker saham online. Cukup buka akun, ikuti prosedur broker, dan mulai berdagang. Sebagai alternatif, Anda dapat berlatih berdagang saham Tesla di Profit.com dalam Turnamen Playtrade atau memilih broker yang disarankan untuk berdagang langsung.

Question 15

Haruskah saya berinvestasi di saham GSK?

Accepted Answer

Berinvestasi di saham membutuhkan penelitian yang mendalam, termasuk menganalisis keuangan perusahaan, berita terkait, dan analisis teknis. Saat ini, rekomendasi analis teknis Tesla menunjukkan rating hold.

Sebelum berinvestasi di GSK, pertimbangkan untuk berlangganan Profit PRO di mana Anda dapat berlatih berdagang di Turnamen Playtrade, mengakses wawasan pasar harian berbasis AI, menyalin Watchlist yang dipilih dengan ahli, dan mengikuti Portofolio Miliarder.

GlaxoSmithKline PLC ADR

Key deals this week: Clorox, Spirit Airlines, GSK, PayPal, and more

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

GSK to buy Rapt Therapeutics in deal valued at $2.2B

GSK turns to insider to be next CEO — and the stock rallies

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit - CNBC

GSK shares break six-session winning streak

GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B

M&A Snapshot: GSK to acquire IDRx in $1.15B deal, expanding in GI cancer therapy

GSK to buy Boston-based IDRx for $1.15 billion

GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx

GSK cuts vaccine sales target on reduced demand

GSK to acquire lupus drug candidate CMG1A46 for up to $850M

GSK settles vast majority of Zantac claims for $2.2 billion

GSK settles two California lawsuits related to heartburn drug Zantac https://t.co/eJ2esK6x6M https://t.co/mWbEdVD5TH

GSK shares jump on win in Delaware court over ongoing Zantac battle

Live news: GSK shares drop as US narrows recommended age range for RSV vaccines - Financial Times

GSK stock falls more at London open following RSV vaccination news

GSK buys RNA therapeutics company for up to $50M

GSK says efficacy of its shingles vaccine remains high after years https://t.co/42U2TgcVNK https://t.co/za9ByvfkxK

GSK lifts long-term outlook following launch of blockbuster vaccine in 2023

GSK to sell 3.2% stake in spin-off Haleon in its third stake sale in under a year https://t.co/kGsGpealJJ https://t.co/KEcaEJSKiv

Sell AstraZeneca, says UBS, which upgrades European rivals including GSK

GSK to buy asthma drug developer for up to $1.4 billion in pipeline push

GSK to buy Aiolos Bio for up to $1.4B to expand respiratory portfolio

GSK looking to boost pipeline with respiratory, auto-immune deals - report

RSV vaccine from GSK shows potential to protect adults 50 to 59

GSK signs shingles vaccine deal with China's Zhifei for around $3 bln - Reuters

GSK signs shingles vaccine deal with China's Zhifei for about $3 bln https://t.co/HKR2ByW68X https://t.co/faStcNiuo6

GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales

GSK completes $2B acquisition of Bellus Health

Movers & Shakers: Virgin Galactic shares tumble, while Trupanian and GSK climb and other stocks on the move

Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says

CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60

GSK says RSV vaccine for older adults provides protection over two seasons

Pfizer and GSK to battle for share of new RSV vaccine market: Report - Business Standard

GSK employees to escalate strike action in June -union https://t.co/lfM6mkSev8 https://t.co/mxAlKNty8E

GSK sells $1 bln discounted stake in spin-off Haleon https://t.co/L0DHhiGVlp https://t.co/Dxw3FSHmkk

GSK sells $1 bln discounted stake in spin-off Haleon https://t.co/GGv2gtgmOv https://t.co/vVcrjOKQDS

US FDA approves first RSV vaccine from GSK https://t.co/g0u618p8Um https://t.co/EfmP1gr5UG

US FDA approves first RSV vaccine from GSK https://t.co/XRxlh1Kb7V https://t.co/MLuETHjgQ5

US FDA approves first RSV vaccine from GSK https://t.co/pKyuC0Gv8y https://t.co/I9MuAEyclt

US FDA approves first RSV vaccine from GSK https://t.co/GwVWqGYarV https://t.co/XsjEctVMMe

GSK stays strong as healthy sales beat expectations https://t.co/yJsarsKh0O https://t.co/LTq8IcOif8

Dow Jones Newswires: GSK first quarter profit dips to £1.49 billion but beat analyst forecasts

GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view https://t.co/NotwPwzBcr https://t.co/1W4grUsGuT

GSK bets $2 bln on Bellus cough drug to soothe pipeline fears https://t.co/c4NbMBnwRN https://t.co/tEq4H12WYO

Movers & Shakers: Bellus Health’s stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss

GSK bets $2 bln on Bellus cough drug to soothe pipeline fears https://t.co/qMu6lpyKgS https://t.co/LAzmvNjNw7

Bellus surges ~100% after GSK reaches deal to acquire cough drugmaker for ~$2B

FAQ